Le Teuff, Gwénaël <br/><br/>
Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc Bayesian analysis: A European ITCC study.  [electronic resource] 

 -  Pediatric blood & cancer  01 2020 
 - e28032 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1545-5017 
<br/><br/><label>Standard No.: </label>10.1002/pbc.28032  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Bayes Theorem<br/>Central Nervous System Neoplasms--drug therapy<br/>Cerebellar Neoplasms--drug therapy<br/>Child<br/>Child, Preschool<br/>Drug Resistance, Neoplasm--drug effects<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Infant<br/>Male<br/>Medulloblastoma--drug therapy<br/>Neoplasm Recurrence, Local--drug therapy<br/>Neuroectodermal Tumors, Primitive--drug therapy<br/>Prognosis<br/>Salvage Therapy<br/>Survival Rate<br/>Temozolomide--administration & dosage<br/>Topotecan--administration & dosage<br/>Young Adult